24 results about "Transplanted kidney" patented technology

The invention relates to a renal transplantation post-operation rejection risk monitoring and early warning method and a renal transplantation post-operation rejection risk monitoring and early warning system. The method comprises the steps of collecting recipient nursing monitoring data, laboratory indexes and transplanted kidney ultrasonic blood flow parameters in a follow-up visit period, performing timestamp alignment, deletion processing and standardization on multi-source data, extracting features to construct a time sequence feature sequence, inputting the time sequence feature sequence into a pre-training risk prediction model, outputting the rejection reaction occurrence probability of the next period, and forming a risk trend. Calculating a nursing sensitive index contribution weight based on the model contribution information, and screening a target nursing monitoring index; and establishing an individualized baseline model to obtain a baseline value and an allowable fluctuation interval, extracting characteristics such as deviation amplitude, direction, rate, fluctuation and continuous deviation duration and the like, and performing individualized calibration on the occurrence probability to obtain a calibration risk score. When the threshold value is not reached and the trend is not triggered, generating a nursing monitoring suggestion of the next period; and pushing early warning and generating grading intervention suggestions when a threshold value is reached or a trend is triggered.

The invention relates to the technical field of medical instruments, and discloses a disposable simple in-vitro transplantation renal artery perfusion apparatus which comprises a buckle seat, a panel and a perfusion tube, a perfusion tube mounting hole is formed in the middle of the panel, the perfusion tube is connected in the perfusion tube mounting hole in the middle of the panel in a penetrating mode, one end of the perfusion tube is connected with a perfusion tube, and the other end of the perfusion tube is connected with a drainage tube. The other end is inserted into the abdominal aorta; the buckle base comprises a bottom plate and side plates arranged at the two ends of the two sides of the bottom plate, a penetrating hole is formed in the middle of the bottom plate, and clamping grooves are formed in the inner sides of the side plates. The disposable simple in-vitro transplantation renal artery perfusion apparatus can be effectively fixed at an opening of an artery, perfusion can be carried out by connecting an infusion tube, assistance of other people is not needed, fixation is good, perfusate cannot leak out to cause waste, and intima of the artery cannot be damaged to cause series complications.

The invention provides application of FXR protein as a target spot in preparation of a medicine for relieving and / or treating renal toxicity of tacrolimus, and belongs to the technical field of biological medicine. The invention proves that the activity or expression level of the FXR protein is regulated in a targeted manner, so that the Tacrolimus-induced renal tubule epithelial cell vacuolation and renal tubule injury can be effectively prevented or relieved, and the abnormal rise of early renal injury markers such as urine NAG enzyme and the like is reduced, thereby directly improving the renal toxicity problem of Tacrolimus. The invention provides a new drug action target and a treatment strategy for clinic, and by developing an FXR agonist or a gene intervention means, the long-term renal injury risk of tacrolimus can be reduced while the anti-rejection curative effect is maintained, the transplanted kidney function and the survival time of a patient are prolonged, and the clinical application prospect is wide. And an effective means is provided for solving the unsatisfied clinical demand of the renal toxicity of the tacrolimus after the transplantation operation.

This invention discloses the application of quinolinic acid in the preparation of drugs for the prevention and treatment of acute kidney injury (AKI). AKI refers to acute kidney injury induced by renal ischemia-reperfusion. The drug is an oral formulation used for prophylactic administration in high-risk individuals undergoing iatrogenic procedures at potential AKI risk, and for pretreatment of ischemic conditions in transplanted kidneys. Experiments have shown that administration of quinolinic acid significantly reduces serum urea nitrogen levels in AKI mice, alleviates renal tissue morphological damage in AKI mice, and reduces the expression level of the renal tubular injury factor NGAL protein in AKI mice, demonstrating significant clinical value in the prevention and treatment of AKI.

Systems and methods for identifying risk of kidney graft failure in a subject are provided. An image of a graft biopsy is obtained, the image representing at least a subset of a plurality of morphological classes including a tissue compartment and inflammation class. The image is inputted into a trained model that identifies, as output, for each morphological class in at least the subset, corresponding objects in the image that fall within the morphological class. For each morphological class, corresponding digital features are generated comprising a first subset of individual feature scores obtained using the objects for the morphological class and a second subset of composite feature scores obtained by combining individual feature scores. Digital features for each morphological class are compared to a reference criterion, thus determining risk of kidney graft failure.

The invention discloses application of nintedanib in preparation of a medicine for treating plant migration and plant mineralization, and belongs to the technical field of biological medicine. The research shows that the nintedanib has the effects of reducing deposition of extracellular matrix of an allogeneic kidney transplantation model mouse, improving renal tubular atrophy, relieving mouse CD206 + macrophage infiltration and reducing rejection injury degree and immune infiltration degree of kidney grafts after being administered under the administration dosage without generating liver and kidney toxicity and intestinal side effects; the lesion process of mouse chronic transplanted kidney rejection is obviously slowed down, and the damage of excessively activated inflammatory cells to the transplanted kidney is reduced. The results show that nintedanib can delay the progress of chronic transplantation renal fibrosis.

The invention discloses application of alpha-ketoglutaric acid in preparation of a medicine for preventing and / or treating antibody-mediated rejection reaction, and belongs to the technical field of biological medicine. According to the application, an acute antibody-mediated rejection reaction model of mouse skin pre-sensitization combined with kidney transplantation is constructed, and alpha-KG is applied for intervention. Results show that the alpha-KG can significantly improve renal functions (serum creatinine and urea nitrogen are reduced), prolong survival time of the transplanted kidney, relieve histological injury of the transplanted kidney (Banff score is reduced), inhibit deposition of complement C3d, reduce the level of a specific antibody (DSA) of a peripheral blood donor, down-regulate expression of kidney local inflammatory factors (Tnf, Il-6, Il-1beta and Nos2), regulate immune cell infiltration in the transplanted kidney, and improve the survival rate of the transplanted kidney. Comprising the steps of reducing transplantation kidney mononuclear / macrophage infiltration, reducing the proportion of transplantation kidney pro-inflammatory macrophages and increasing the proportion of repair macrophages. The application provides a new drug choice for treating the acute antibody-mediated rejection of the transplanted kidney, and has an important clinical application prospect.

Provided herein are methods and compositions for treating kidney-related disease conditions and complications, such as Berger's disease, and for preventing transplant rejection. For example, the present disclosure describes a method of improving function of a transplanted kidney in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds CD40 ligand.

The present invention provides a method for detecting the TLR10 rs28393318 genotype and its application in evaluating the long-term graft function of renal transplant recipients. The genotype of TLR10 rs28393318 can be used to predict the long-term graft function of renal transplant patients, thereby guiding clinical treatment to improve the long-term survival rate of transplanted kidneys. Therefore, the method for detecting the TLR10 rs28393318 genotype provided by the present invention can improve the prediction sensitivity of the long-term graft function of renal transplant recipients, provide strategies for preparing corresponding prediction or evaluation products, and has great social and economic benefits.

This invention relates to a diagnostic kit for assessing transplant rejection status, belonging to the field of biomedical technology. The invention obtains data on the relative proportions and absolute counts of various immune cell populations in peripheral blood, and measures the ultrasound hemodynamic parameters of the transplanted kidney, including the interlobar artery resistance index and the renal aortic resistance index. It then uses the formula y1 = -1.228a + 0.008b – 0.009c to determine whether acute rejection exists. In the formula, the donor kidney type is defined as variable a, with living donor kidney = 0 and deceased donor kidney = 1; the absolute value of peripheral blood CD4 is defined as a continuous variable b; the absolute value of peripheral blood CD8 is defined as a continuous variable c; and when y1 > 0.5, acute rejection is determined. This invention makes the diagnosis of the immune status of transplanted kidneys non-invasive, optimizing the kidney transplant diagnosis and treatment process.

The invention relates to the technical field of biosensors and wireless health monitoring, and particularly discloses a renal rejection monitoring system based on a wireless implantable biosensor. The system comprises a wireless implantable biosensor array, an in-vivo signal preprocessing unit, an in-vitro data receiving and synchronizing device, a multi-modal heterogeneous data fusion engine and a space-time diagram neural network prediction model, immune and metabolism multi-dimensional biomarkers are collected around a transplanted kidney in real time, a dynamic'immunity-metabolism 'knowledge graph is constructed, and accurate prediction and graded early warning of rejection risks are achieved by means of space cascading and time evolution laws of time-space diagram neural network modeling signals. By the adoption of the technical scheme, sub-clinical rejection signals can be recognized before conventional indexes such as creatinine are abnormal, a window is intervened in advance, meanwhile, long-term non-invasive monitoring is achieved through wireless low-power-consumption design, and the accuracy and the intelligent level of postoperative management are improved.

This invention relates to the application of reagents for detecting biomarkers in the preparation of non-invasive diagnostic products for renal interstitial fibrosis and chronic progressive injury, belonging to the field of biotechnology. The biomarkers are SNX3, VPS4B, and SMO, derived from urinary extracellular vesicles, and their expression levels increase with the degree of transplanted kidney fibrosis. The urinary extracellular vesicle separation method of this invention effectively removes urinary glomerulonephrine entangled with vesicles during ultracentrifugation without affecting the structural integrity of the extracellular vesicles or the expression of the marker proteins. The biomarkers of this invention have excellent diagnostic capabilities for transplanted kidney fibrosis and also demonstrate outstanding ability in diagnosing chronic progressive injury of transplanted kidneys, predicting the risk of transplanted kidney failure, and assessing renal fibrosis in chronic kidney disease. They possess advantages such as good stability, high specificity, and high sensitivity, and are simple to operate with a short detection cycle, enabling non-invasive diagnosis or prognostic monitoring of fibrosis in both transplanted and non-transplanted kidneys.

A method of use of a synthetic SCGB, and compositions thereof, to prevent the development or reduce the development of antibodies against a foreign antigen or set of antigens in the subject that receives the antigen(s) is provided. A synthetic SCGB being recombinant human CC10 protein is provided. The foreign antigen(s) is / are a cell, tissue or organ from a donor subject is administered, introduced, or transplanted into a recipient subject, a lung transplant, transplanted kidney, heart, liver, hematopoietic cell, or any other tissue or organ, antigen(s) is / are from human or non-human origin, purified therapeutic proteins or other drugs, food or drink, self-antigen or an allergen.

The invention relates to application of a reagent for detecting a biomarker in preparation of a product for noninvasive diagnosis of renal interstitial fibrosis and chronic progressive injury, and belongs to the technical field of biology. The biomarkers are SNX3, VPS4B and SMO derived from urine extracellular vesicles, and the expression level is increased along with the increase of the fibrosis degree of the transplanted kidney. According to the separation method of the urine extracellular vesicles, the urine regulatory proteins wound with the vesicles in the ultracentrifugation process can be effectively removed, and the structural integrity of the extracellular vesicles and the expression of marker proteins are not influenced; the biomarker disclosed by the invention has excellent transplanted kidney fibrosis diagnosis capability, and also has excellent capabilities in diagnosing chronic progressive injury of the transplanted kidney, predicting the risk of dysfunction of the transplanted kidney and renal fibrosis of chronic kidney diseases. The kit has the advantages of good stability, strong specificity and high sensitivity, is simple and convenient to operate and short in detection period, and can be used for non-invasive diagnosis or prognosis monitoring of transplanted kidney or non-transplanted kidney fibrosis.

The invention discloses a specific reversible capture method for transplanted kidney exfoliated cells. The method comprises the following steps: (1) preparing a micro-fluidic chip; (2) conveying the magnetic beads of which the surfaces are modified with the EpCAM antibodies into a micro-fluidic chip, and then placing the micro-fluidic chip on a magnet for stabilization, so that the magnetic beads are uniformly and stably distributed in the micro-fluidic chip; (3) conveying peripheral blood containing the transplanted kidney exfoliated cells into the micro-fluidic chip, so that the transplanted kidney exfoliated cells are captured by the magnetic beads through the EpCAM antibodies modified on the surfaces of the magnetic beads; and (4) after the capture is completed, removing the magnet, and then introducing a release reagent into the micro-fluidic chip, so that the captured transplanted kidney exfoliated cells with the magnetic beads are released from the chip. The invention provides a promising solution for early diagnosis of kidney transplantation rejection, provides insight for improving the long-term survival rate of kidney transplantation, clarifies the mechanism of immunological rejection, and supports precise treatment of clinical kidney transplantation rejection.

1. Name of the Design Product: Airbag Abdominal Pressure Belt. 2. Use of the Design Product: After major abdominal surgeries such as renal puncture, liver transplantation, and kidney transplantation, the abdominal pressure belt is used to apply pressure bandaging to the abdomen. 3. Design Key Points of the Design Product: Lies in the shape. 4. Picture or Photograph that Best Illustrates the Design Key Points: Stereogram.

The utility model belongs to the technical field of auxiliary rehabilitation belts, and discloses a kidney transplantation postoperative auxiliary rehabilitation belt which comprises an external bandage, the outer side of the external bandage is fixedly connected with a supporting frame, the interior of the supporting frame is fixedly connected with a fixed guide rail, one side of the fixed guide rail is slidably connected with a first rotating block, and the other side of the fixed guide rail is slidably connected with a second rotating block. A first rotating rod is rotatably connected to the outer side of the first rotating block, a supporting rod is rotatably connected to one end of the first rotating rod, a second rotating rod is rotatably connected to one side of the supporting rod, a second rotating block is rotatably connected to the inner side of one end of the second rotating rod, and a sliding guide rail is slidably connected to the outer side of the second rotating block; by means of the technical scheme, the problems that in the prior art, in the using process, the back waist of a patient cannot be effectively supported, the transplanted kidney is possibly affected when the patient bends down to move, the recovery time is affected, the transplanted kidney area cannot be stably supported, and the using performance is poor are solved.

The present application describes and claims a novel method for identifying and stratifying the risk of developing a BK virus nephropathy (“Nx BK-v” below) in patients having undergone a kidney transplant. This method uses an index combining at least three bio-markers: i) the intensity of the anti-BK-v memory T lymphocyte response (memory T lymphocytes which are specific to BK-v, hereinafter “LTm anti-BK-v”), ii) the number of occurrences of incompatibility in the HLA alleles of class I and class II between the donor and the recipient of the graft, taking into account iii) the viral charge of the BK-v virus in the whole blood of the patient. The present method allows a very precise evaluation of the risk of developing an Nx BK-v during the months following the test with the aim of optimising the immuno-suppressive treatment in order to better preserve the transplanted kidney.

The invention relates to the technical field of medical rehabilitation instruments, in particular to kidney transplantation post-operation rehabilitation equipment based on an artificial intelligence technology, which comprises a base, a push rod, a control panel, a back support plate, a plurality of rollers, two lifting tables, a rotating plate, two stable seats, two support seats, two support sleeves and two lifting rods, the rotating plate is used for supporting movement of the chest of a patient, and the back supporting plate is used for providing limiting support for the back position corresponding to the kidney of the patient; a rehabilitation optimization system is arranged in the control panel and used for obtaining real-time forward inclination angle data of the patient and the actual walking distance of the patient, conducting correlation analysis, judging the physical power condition of the patient based on an AI physical power evaluation model and automatically generating an adaptive movement distance. The physical strength condition of the patient is judged by monitoring the forward leaning action when the patient walks, then a walking rehabilitation scheme is provided in a targeted mode, and the problems that when the patient gets out of bed walking training after the kidney transplantation operation, due to insufficient physical strength, the body leans forward, a wound is pulled, and a transplanted kidney area is pressed are effectively solved.

The present technology provides methods of reducing ischemia-reperfusion (IR) injury in a kidney to be transplanted comprising administering an effective amount of a bioavailable nanoparticle comprising NAD+ and / or NADH to the kidney prior to surgical transplantation of the kidney into a subject. Additionally, the present technology provides methods of reducing ischemia-reperfusion (IR) injury to a transplanted kidney in a subject comprising administering an effective amount of a bioavailable nanoparticle comprising NAD+ and / or NADH to the subject after transplantation of the kidney into the subject and also provides bioavailable nanoparticles comprising NAD+ and / or NADH for use in such methods.

Provided herein are methods and compositions for treating kidney-related diseases disorders, and complications, such as Berger's disease and for preventing transplant rejections. For example, the present disclosure describes methods of improving transplanted kidney function in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds CD40 ligand.

The present invention belongs to the field of biomedical materials, and discloses a class of organic near-infrared second near-infrared region (NIR-II) luminescent materials based on pyrrolo[2,3-b:4,5-b']diindole derivatives, a preparation method thereof, and an application thereof in kidney transplantation surgery. In the present invention, a nine-ring pyrrole derivative is used as an electron-donating group, and 2-(5,6-difluoro-3-oxo-2,3-dihydro-1H-inden-1-ylidene) malononitrile with strong electron-withdrawing ability is combined to design an organic NIR-II molecule with an A-D-A structure. Then, through simple aggregation, an AIE aggregate DIPT-ICF Aggs with both NIR-II absorption and emission is obtained. The present invention exhibits excellent transplanted kidney angiography and transplanted kidney reperfusion imaging capabilities in kidney transplantation surgery, has a wide application prospect in the field of biomedicine, and is expected to be widely applied in the field of fluorescence imaging for surgical operations.

Methods for assessing the likelihood of delayed graft function (DGF) of a donor kidney in a kidney transplant recipient are provided. Additionally, methods for determining the likelihood of requiring dialysis in a kidney transplant recipient are provided. Such methods include measuring expression of at least one gene in a sample from the kidney for transplant or from the transplanted kidney.

This invention relates to the field of biomarkers and their applications, specifically to biomarkers for delayed recovery of transplanted kidney function after kidney transplantation and their applications. Using a combination of metabolomics methods and enzyme-linked immunosorbent assay (ELISA), analysis revealed that the expression of the differentially expressed metabolite 8-hydroxydeoxyguanosine (8-OHdG) was significantly increased in patients with end-stage chronic kidney disease after kidney transplantation. High expression may be related to the severity of pre-transplant chronic kidney disease. The serum 8-OHdG concentration one day after kidney transplantation has a certain diagnostic value for the occurrence of delayed recovery of kidney function (DGF). Serum 8-OHdG levels fluctuate considerably and are correlated with post-operative changes in kidney function, providing a reference for clinically seeking reliable biological indicators for early diagnosis of whether DGF has occurred in kidney transplant patients, and aiding in the clinical evaluation of donor kidney quality and guiding subsequent treatment for patients.